Enable Biosciences

Executive Summary

Enable Biosciences, a diagnostics company spun out of UC Berkeley and Stanford in 2016, is developing next-generation tools for predictive medicine. The company focuses on antibody-based tests for autoimmune and infectious diseases, leveraging its proprietary technology to enable early detection and monitoring. With over 150,000 tests performed, Enable has established partnerships with leading institutions including Stanford Healthcare, Harvard Medical School, the California Department of Public Health, and JDRF. These collaborations underscore the clinical utility and commercial traction of its diagnostic platform. Enable operates in the rapidly growing predictive diagnostics market, driven by increasing demand for personalized medicine and early disease intervention. The company's technology offers advantages in sensitivity and multiplexing, positioning it for expansion into new disease areas. Key near-term opportunities include scaling its type 1 diabetes risk test and pursuing regulatory clearances for additional indications. With a strong academic foundation, validated partnerships, and a growing test volume, Enable is well-positioned to capture market share in the autoimmune diagnostics space.

Upcoming Catalysts (preview)

• Q4 2026FDA clearance or CE marking for expanded type 1 diabetes autoantibody panel75% success
• Q2 2026Announcement of new pharma partnership for drug monitoring or companion diagnostics65% success
• Q3 2026Publication of clinical validation data in a major journal for a new test80% success